Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SR T100

Drug Profile

SR T100

Alternative Names: SR-T100

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator G&E Herbal Biotechnology
  • Class Antineoplastics; Phytotherapies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Condylomata acuminata
  • No development reported Vulvar intraepithelial neoplasia

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-0 development in Vulvar-intraepithelial-neoplasia in Taiwan (Topical, Gel)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Actinic keratosis in Taiwan (Topical, Gel)
  • 15 Jul 2019 G&E Herbal Biotechnology suspends a phase II trial in Warts in Taiwan, due to budget issue (NCT01796795)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top